<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538940</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCIRD-6181</org_study_id>
    <secondary_id>1U01GH000152</secondary_id>
    <nct_id>NCT01538940</nct_id>
  </id_info>
  <brief_title>Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand</brief_title>
  <official_title>Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of a new intradermal formulation of the trivalent&#xD;
      inactivated influenza vaccine compared to the standard intramuscular vaccine in HIV-infected&#xD;
      men who have sex with men in Bangkok, Thailand. Relative efficacy of the two different&#xD;
      formulations of influenza vaccine will be assessed by comparing immunologic responses to&#xD;
      vaccine between the two study arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>30 days</time_frame>
    <description>Frequency of 4-fold or greater increase in serum hemagglutination inhibition antibody titers against each viral strain in the vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of 4-fold or greater increase in serum hemagglutination inhibition antibody titers against each viral strain in the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of 4-fold or greater increase in serum hemagglutination inhibition antibody titers against each viral strain in the vaccine</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>HIV+, CD4&lt;200, ID vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+, CD4&lt;200, IM vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+, CD4&gt;=200, ID vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+, CD4 &gt;=200, IM vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-, ID vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-, IM vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intradermal vaccine</intervention_name>
    <description>15ug</description>
    <arm_group_label>HIV+, CD4&lt;200, ID vaccine</arm_group_label>
    <arm_group_label>HIV+, CD4&gt;=200, ID vaccine</arm_group_label>
    <arm_group_label>HIV-, ID vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular vaccine</intervention_name>
    <description>15ug</description>
    <arm_group_label>HIV+, CD4 &gt;=200, IM vaccine</arm_group_label>
    <arm_group_label>HIV+, CD4&lt;200, IM vaccine</arm_group_label>
    <arm_group_label>HIV-, IM vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Thai men by nationality who have sex with men&#xD;
&#xD;
          -  HIV-infected or HIV-uninfected men&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Availability and commitment for 12 months of study follow-up (3 study visits)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men with severe allergies to chicken eggs (they will specifically be asked about&#xD;
             severe egg allergies during the screening visit; appendix C1)&#xD;
&#xD;
          -  Men &gt; 60 years of age&#xD;
&#xD;
          -  Men who have had a severe reaction to influenza vaccine in the past&#xD;
&#xD;
          -  Men with a history of Guillain-Barr√© Syndrome&#xD;
&#xD;
          -  Men who received influenza vaccine within 12 months prior to enrollment&#xD;
&#xD;
          -  Men who are on steroid therapy or other immunosuppressant medications&#xD;
&#xD;
          -  Men who received any vaccine in the 4 weeks prior to the first study visit or who plan&#xD;
             to receive a vaccine (other than influenza vaccine provided through the study&#xD;
             protocol) in the 4 weeks following the first study visit&#xD;
&#xD;
          -  Men who received an experimental agent (vaccine, drug, biologic, device, blood&#xD;
             product, medication) within 1 month prior to enrollment in this study, or expect to&#xD;
             receive an experimental agent during the 12 month study period&#xD;
&#xD;
          -  Men who have any condition, in the opinion of the investigator, that would place them&#xD;
             at an unacceptable risk of injury or render them unable to meet requirements of the&#xD;
             protocol. (e.g., severe reaction to another vaccine, blood clotting disorder,&#xD;
             inflammatory skin condition).&#xD;
&#xD;
          -  Foreign (non-Thai) nationality&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charung Muangchana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prasert Thongcharoen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Influenza Foundation of Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Silom Community Clinic</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pornchai Sornsathapornkul, RN</last_name>
      <phone>+66-2-634-2917</phone>
      <email>fnpst@diamond.mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.silomclinic.in.th/</url>
    <description>Website for clinic where the study is being conducted.</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Thailand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

